Study #2021-0240
A Phase Ib/II trial to evaluate Safety, Tolerability and Efficacy of aurora kinase inhibitor LY3295668 in combination with Osimertinib for patients with EGFR-mutant Non-small Cell Lung Cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
Aurora A Kinase Inhibitor LY3295668, Osimertinib
Description
This phase Ib/II trial studies the side effects and best dose of aurora A kinase inhibitor LY3295668 when given together with osimertinib in patients with EGFR-mutant non-squamous non-small cell lung cancer that has spread to other places in the body (advanced or metastatic). Aurora A kinase inhibitor LY3295668 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving aurora A kinase inhibitor LY3295668 in combination with osimertinib may help control EGFR-mutant non-squamous non-small cell lung cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Study phase:
Physician name:
Xiuning Le
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-844-961-3045
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.